$NVNO News

enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman

enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

enVVeno Medical Files Prospectus To Offer And Sell Securities For Up To $100M

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

enVVeno Announces Publication Of Peer-Reviewed Health Economics Study Supporting Venous Valve Therapy; Findings May Support Future Coverage And Reimbursement Decisions

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

enVVeno Medical Q2 EPS $(5.37) Up From $(11.55) YoY

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

EnVVeno Medical Issued U.S. Patent For Its Intellectual Property Portfolio Supporting Its enVVe Transcatheter Replacement Venous Valve System To Treat Venous Disease

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical Q1 EPS $(5.89) Misses $(0.28) Estimate

One enVVeno Medical Insider Raised Their Stake In The Previous Year

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve